Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12 2024 - 8:00AM
Science 37 Holdings, Inc., a leader in enhancing patient access to
clinical trials, announced the final enrollment figures from its
20-month engagement with a clinical-stage drug development company
advancing novel small molecule therapeutics for systemic
neuro-immune disorders.
Science 37 augmented the recruitment and enrollment activities
taking place at study sites nationwide for this ongoing Phase 2
trial evaluating the effects of EP547 in patients with Cholestatic
Pruritus due to Primary Biliary Cholangitis (PBC) or Primary
Sclerosing Cholangitis. The study protocol mandated a highly
specific patient population, requiring participants to undergo
evaluation against rigorous inclusion and exclusion criteria.
Leveraging its proprietary Metasite™ and Patient
Recruitment solutions, Science 37 contributed 21% of all randomized
study participants between September 2022 and April 2024. Science
37 surpassed its contracted enrollment goal, achieving an average
enrollment rate of 1 patient per month, compared to the 0.1
patients per month rate at each of the 51 participating traditional
brick-and-mortar sites.
“Traditional recruitment methods are geographically limited,
whereas Science 37 can recruit and enroll patients located
anywhere, not just within a certain travel radius of a trial site.
This significantly broadens the pool of qualified participants,
which is vital for rare disease research,” explained Erica
Prowisor, SVP of Patient and Provider Networks at Science 37.
Science 37’s Patient Recruitment is available on a standalone
basis to clinical research sponsors and CROs looking to enhance
their patient enrollment efforts, or in combination with Science
37’s industry-leading flagship Virtual Site, the Metasite™, as part
of an accelerated research offering. For more information, please
visit www.science37.com.
About Science 37
Science 37’s mission is to accelerate clinical research by
enabling universal trial access for patients. Through our
solutions; the Metasite™ and Patient Recruitment, we accelerate
enrollment by expanding the reach of clinical trials to patients
beyond the traditional site and rigorously qualifying patients
prior to referring them to a traditional site. Our solutions are
powered by a proprietary technology stack with in-house medical and
operational experts that enhance quality through standardized
workflows and best-in-class study orchestration. To learn more,
visit www.science37.com, or email science37@science37.com.
To view studies that Science 37 is actively recruiting for,
please visit https://studies.science37.com/current-studies.
Media Inquiries
Science 37PR@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Aug 2023 to Aug 2024